Castle Creek Biosciences develops personalized gene therapies using autologous fibroblast technology to treat Dystrophic Epidermolysis Bullosa, a rare genetic skin disorder that causes severe blistering. Their approach aims to provide targeted relief for patients suffering from this debilitating condition by addressing the underlying genetic causes.
Funding
$344.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic skin disorder characterized by severe blistering, causing significant pain and complications for affected individuals. Current treatments offer limited relief, failing to address the underlying genetic defect responsible for the condition.
Solution
Castle Creek Biosciences is developing personalized gene therapies for Dystrophic Epidermolysis Bullosa (DEB) using an autologous fibroblast technology platform. This approach involves collecting a patient's own skin cells (fibroblasts), genetically modifying them to correct the DEB-causing mutation, and then transplanting the corrected cells back into the patient's skin. The genetically corrected fibroblasts produce functional collagen, addressing the root cause of DEB and promoting wound healing and reducing blistering. This targeted gene therapy aims to provide long-term relief and improve the quality of life for individuals suffering from DEB.
Target Audience
The primary target audience includes patients diagnosed with Dystrophic Epidermolysis Bullosa (DEB) and their families, as well as physicians specializing in dermatology and genetic disorders.
Features
- Autologous fibroblast technology utilizing patient's own cells to minimize immune rejection.
- Ex-vivo gene editing to correct the mutated gene responsible for collagen production.
- Targeted delivery of genetically modified fibroblasts to affected areas of the skin.
- Production of functional collagen VII to restore skin integrity and reduce blistering.